Sugi Predict

Sugi Predict / Targets / DAGLA

DAGLA

Diacylglycerol lipase-alpha · Q9Y4D2 · DAGLA on Sugi Atlas →

20,809 patent compounds predicted against DAGLA, 11,549 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1811297 SCHEMBL1811297 0.86 14/20
SCHEMBL712201 SCHEMBL712201 1.00 12/20
SCHEMBL712202 SCHEMBL712202 1.00 12/20
SCHEMBL713349 SCHEMBL713349 1.00 12/20
SCHEMBL715602 SCHEMBL715602 1.00 12/20
SCHEMBL715603 SCHEMBL715603 1.00 12/20
SCHEMBL1172713 SCHEMBL1172713 1.00 12/20
SCHEMBL714039 SCHEMBL714039 0.62 12/20
SCHEMBL715649 SCHEMBL715649 0.58 12/20
SCHEMBL716057 SCHEMBL716057 0.60 11/20
SCHEMBL716058 SCHEMBL716058 0.60 11/20
SCHEMBL639690 SCHEMBL639690 0.47 11/20
SCHEMBL537727 SCHEMBL537727 0.64 10/20
SCHEMBL713881 SCHEMBL713881 1.00 9/20
SCHEMBL713678 SCHEMBL713678 0.90 9/20
SCHEMBL713679 SCHEMBL713679 0.90 9/20
SCHEMBL712215 SCHEMBL712215 0.70 9/20
SCHEMBL715188 SCHEMBL715188 0.67 9/20
SCHEMBL1630063 SCHEMBL1630063 0.62 9/20
SCHEMBL908981 SCHEMBL908981 0.52 9/20

Clinical trials — most relevant to DAGLA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effects of Eicosapentaenoic Acid (EPA), Gamma-Linolenic Acid (GLA) and Antioxidants in the Treatment of Sepsis PHASE4COMPLETED
n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis PHASE4COMPLETED
DAWL (Dairy and Weight Loss) Study PHASE4WITHDRAWN
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency PHASE3COMPLETED
Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus EARLY_PHASE1COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease EARLY_PHASE1COMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Oxidative Lipidomic Biomarkers During Mechanical Ventilation in Critically Ill Patients (OXY-BAL). nanRECRUITING
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism nanCOMPLETED
Effect of Cryolipolysis on Insulin Resistance nanUNKNOWN
Lysosomal Acid Lipase (LAL) Deficiency Registry nanRECRUITING
Fatty Acid Regulation of Platelet Function in Diabetes nanCOMPLETED
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism nanCOMPLETED
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans nanCOMPLETED
Fighting Fatty Liver in India nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV nanNOT_YET_RECRUITING
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
Healthy Fatty Acids in Transition nanCOMPLETED
High Density Lipoprotein Subspecies and Coronary Disease nanCOMPLETED
The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD. nanENROLLING_BY_INVITATION
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects) nanUNKNOWN
Fat Tissue Microperfusion to Measure Leptin Secretion and Its Relations With Fat Breakdown in Humans nanCOMPLETED
Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease nanUNKNOWN
Acute Pancreatitis Targets (APT) Study nanCOMPLETED
A Longitudinal Study on Short-term Effects of Gastric Bypass on Glucose Homeostasis in Obesity nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DAGLA binder may also engage these)

ProteinNameSimilarity
Q6WQJ1 — 1.000 Q6WQJ1 →
Q5YLM1 — 1.000 Q5YLM1 →
A5D794 — 0.990 A5D794 →
E9PUQ8 — 0.990 E9PUQ8 →
Q80WQ6 — 0.990 Q80WQ6 →
Q6GMF8 — 0.989 Q6GMF8 →
Q6ZPQ6 — 0.989 Q6ZPQ6 →
O35954 — 0.989 O35954 →
A9L8T6 — 0.989 A9L8T6 →
O00562 — 0.989 O00562 →
Q499S9 — 0.989 Q499S9 →
Q9BZ72 — 0.989 Q9BZ72 →
Q16760 — 0.988 Q16760 →
B0VX73 — 0.988 B0VX73 →
Q9VKA4 — 0.988 Q9VKA4 →
Q6PIX5 — 0.988 Q6PIX5 →
Q5BKX6 — 0.988 Q5BKX6 →
Q5SNQ7 — 0.988 Q5SNQ7 →
Q9JHD2 — 0.988 Q9JHD2 →
DAGLB Diacylglycerol lipase-beta 0.987 landscape →
P0C1S9 — 0.987 P0C1S9 →
Q6PAR5 — 0.987 Q6PAR5 →
Q5JCS6 — 0.987 Q5JCS6 →
Q93971 — 0.987 Q93971 →
Q00M95 — 0.987 Q00M95 →
PIK3C2B Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta 0.987 landscape →
Q96CC6 — 0.987 Q96CC6 →
Q16625 — 0.986 Q16625 →
Q6ZPS6 — 0.986 Q6ZPS6 →
Q86XP1 — 0.986 Q86XP1 →